GLP-1 Receptor Agonists in the Treatment of Obesity: A Narrative Review of Current Therapeutic Methods

Authors

DOI:

https://doi.org/10.12775/QS.2026.55.71099

Keywords

Glucagon-Like Peptide-1 Receptor Agonists, obesity, semaglutide, tirzepatide, liraglutide, weight loss

Abstract

Introduction. Obesity is now considered to be one of the largest public health challenges of the twenty-first century, with over one billion adults affected. With conventional treatments such as lifestyle modifications and bariatric surgery being either ineffective or unavailable to the majority of obese individuals, there is an urgency for the development of safe and effective pharmacologic therapies. GLP-1 receptor agonists have developed into a unique and highly successful class of drugs that produce clinically relevant weight loss in addition to improving cardiovascular and metabolic risk factors. 

Aim of the Study. This review aims to provide a practical and inclusive summary of GLP-1 receptor agonist therapy in obesity, focusing on mechanism of action, currently approved agents, clinical effectiveness, safety profiles and next generation therapeutic approaches. 

Methodology. A literature search was conducted in PubMed/MEDLINE and ClinicalTrials.gov, covering publications from 2015 to March 2026. Randomized controlled trials, systematic reviews, meta-analyses, and expert consensus papers were prioritized.  

Conclusions. The GLP-1 receptor agonists represent a paradigm shift in the treatment of obesity, achieving weight reductions of up to 21%. Both medications also appear to reduce cardiovascular disease risk in non-diabetic populations. While gastrointestinal side effects are the most commonly reported adverse reactions associated with these medications they can be effectively managed. As with all chronic diseases, once these medications are discontinued, patients will experience weight gain which emphasizes the importance of providing long term treatment options. Next-generation agents, including retatrutide and the cagrilintide-semaglutide combination, show even greater weight-reducing potential. Ensuring equitable access, long-term safety monitoring, and individualized treatment approaches remain the key challenges for the field. 

References

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-1050. https://doi.org/10.1016/S0140-6736(23)02750-2

2. Kaplan JM, Zaman A, Abushamat LA. Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?. Curr Cardiol Rep. 2024;26(9):1011-1019. https://doi.org/10.1007/s11886-024-02097-4

3. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. Published 2024 Sep 18. https://doi.org/10.1038/s41392-024-01931-z

4. Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023;24(13):10449. Published 2023 Jun 21. https://doi.org/10.3390/ijms241310449

5. Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782. Published 2024 Aug 30. https://doi.org/10.1016/j.eclinm.2024.102782

6. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. https://doi.org/10.1016/j.molmet.2021.101351

7. Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025;138(6):934-940. https://doi.org/10.1016/j.amjmed.2025.01.021

8. Jones LA, Brierley DI. GLP-1 and the Neurobiology of Eating Control: Recent Advances. Endocrinology. 2025;166(2):bqae167. https://doi.org/10.1210/endocr/bqae167

9. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892

10. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183

11. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. https://doi.org/10.1001/jama.2021.1831

12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038

13. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563

14. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. https://doi.org/10.1056/NEJMoa2410819

15. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. https://doi.org/10.1001/jama.2021.23619

16. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659. https://doi.org/10.1056/NEJMoa2502082

17. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19. https://doi.org/10.1080/00325481.2021.2002616

18. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1):145. Published 2022 Dec 24. https://doi.org/10.3390/jcm12010145

19. Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest. 2026;136(4):e194740. Published 2026 Feb 16. https://doi.org/10.1172/JCI194740

20. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025;26(8):e13929. https://doi.org/10.1111/obr.13929

21. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://doi.org/10.1056/NEJMoa2301972

22. Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. Published 2025 Feb 5. https://doi.org/10.1080/08998280.2025.2456441

23. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647. https://doi.org/10.1056/NEJMoa2502081

24. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity?. Int J Obes (Lond). 2025;49(3):433-451. https://doi.org/10.1038/s41366-024-01473-y

25. Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363. Published 2025 Jul 17. https://doi.org/10.1016/j.eclinm.2025.103363

26. Fredrick TW, Camilleri M, Acosta A. Pharmacotherapy for Obesity: Recent Updates. Clin Pharmacol. 2025;17:305-327. Published 2025 Sep 19. https://doi.org/10.2147/CPAA.S497904

27. Manne-Goehler J, Teufel F, Venter WDF. GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care. JAMA Intern Med. 2025;185(1):8-10. https://doi.org/10.1001/jamainternmed.2024.3579

28. Park C, Kim Y, Raygani S, Grunvald E. A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways. Front Endocrinol (Lausanne). 2025;16:1630199. Published 2025 Sep 11. https://doi.org/10.3389/fendo.2025.1630199

Quality in Sport

Downloads

Published

2026-05-10

How to Cite

1.
BORKOWSKI, Konrad, LEJA, Wiktoria, BŁASZCZAK, Maciej, LATALSKA, Katarzyna, SZCZUPAJ, Maciej, JANUSZCZAK, Radosław, PASTUSZAK, Andżelika, RUDNICKI, Jakub, ZJAWIONY, Julia and ZULFIQAR, Zeeshan. GLP-1 Receptor Agonists in the Treatment of Obesity: A Narrative Review of Current Therapeutic Methods . Quality in Sport. Online. 10 May 2026. Vol. 55, p. 71099. [Accessed 13 May 2026]. DOI 10.12775/QS.2026.55.71099.

Issue

Vol. 55 (2026)

Section

Medical Sciences

License

Copyright (c) 2026 Konrad Borkowski, Wiktoria Leja, Maciej Błaszczak, Katarzyna Latalska, Maciej Szczupaj, Radosław Januszczak, Andżelika Pastuszak, Jakub Rudnicki, Julia Zjawiony, Zeeshan Zulfiqar

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Stats

Number of views and downloads: 32
Number of citations: 0